South Plainfield, NJ – January 11, 2016 –GENEWIZ, a leading global genomics services provider, announced today that it had received an investment to support its growth activities. The terms of the investment were not disclosed. The financing was led by OrbiMed, a healthcare-dedicated investment firm, and participated in by Ampersand Capital Partners and Prime Value Capital Management (PVCM).
“We are excited about the strategic partnership that this investment brings,” said Dr. Steve Sun, GENEWIZ Co-Founder, Chairman and CEO. “GENEWIZ’s steady and strong growth since the company’s founding in 1999 has been organic. With the additional resources and expertise that these investors bring, we are confident about our future success as we enter the next phase of growth.”
With laboratories across the United States, as well as in China and Europe, GENEWIZ provides DNA sequencing, gene synthesis, molecular biology, high throughput/next generation sequencing, bioinformatics, and GLP-CLIA regulatory services to pharmaceutical and biotechnology companies, as well as research facilities around the world.
“We are pleased to have the opportunity to finance GENEWIZ’s growth as a long-term partner. With an excellent track record and outstanding reputation among its customers, GENEWIZ is a clear leader in genomics services,” said Dr. Jonathan Wang, Senior Managing Director, OrbiMed Asia. “We are impressed by the strong management team and look forward to supporting them for many years to come.” Dr. Wang has joined GENEWIZ’s Board of Directors.
“The partnership with OrbiMed and the other investors will allow GENEWIZ to strengthen customer value through enhanced services and advanced technologies,” states Dr. Amy Liao, GENEWIZ Co-Founder, President and COO. “Due to the growth and evolution potential, the genomics R&D services market continues to be invested in by both public and private sectors, and GENEWIZ is proud and excited to be a part of this advancement in supporting scientists with their research discoveries.”
GENEWIZ is a global leader in R&D genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in DNA sequencing, gene synthesis, molecular biology, high throughput sequencing, bioinformatics, and GLP regulatory-compliant services.
Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a global network of laboratories in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; and Tokyo, Japan. For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, and Weibo.
Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. It manages approximately USD$16 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 200 private companies across a wide range of therapeutic categories and stages of development, over 100 of which have been either listed or acquired. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), one of the first pan-Asia healthcare and life sciences-dedicated private equity funds. With over USD$500 million under management, OAP has made PE investments in over 30 companies. www.OrbiMed.com.
About Ampersand Capital Partners
Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed over $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Additional information about Ampersand is available at http://www.ampersandcapital.com.
PVCM is an investment firm that focuses on providing financing to companies with technologies and services in healthcare and clean energy, as well as more traditional industries such as consumer products and agriculture. PVCM was founded by Ms. Sue Chen and Mr. Chenhui Wen in 2009. It is registered in Cayman Islands and it has operation offices in Beijing and Shanghai in China and Dublin in Ireland.